Wanbury LtdNSE WANBURY

Wanbury Ltd. engages in the business of pharmaceutical and related activities, including research. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 1,582 full-time employees. The firm is engaged in the business of pharmaceutical and related activities, including research. The firm operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. The company has approximately 13 API products. The company manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The firm's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).